At the onset of the global pandemic, infectious disease colleagues at Carolina and across the U.S. pivoted quickly and formed the COVID Prevention Network (CoVPN). The network coordinates multiple studies, including the current phase 3 clinical trial for Moderna’s mRNA-1273 COVID-19 vaccine. The overall goal of the national study is to enroll 30,000 volunteers and confirm the vaccine’s efficacy and safety.
Cindy Gay, MD, MPH, assistant professor of medicine in the division of infectious diseases is the primary investigator for the vaccine clinical trial at UNC-Chapel Hill, leading the study at alongside a dedicated team of physicians, nurses, research specialists, pharmacists, medical assistants, data and project managers.
She recently shared her insights about COVID-19 vaccine trials in a Q&A published in the UNC Health and UNC School of Medicine Newsroom.